文献速递慢阻肺

抗ST2单抗astegolimab治疗慢阻肺的2a期试验

Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2022-03-24

COPD-ST2OP是一项单中心、随机、双盲、安慰剂对照2a期试验,纳入中至极重度COPD患者,每4周皮下注射astegolimab 490 mg或安慰剂共44周。48周急性加重率在两组间无显著差异(率比0·78,95%CI 0·53–1·14,p=0·19),但健康状态评分有改善。

要点

  • astegolimab未显著降低48周急性加重率(率比0·78,p=0·19)。
  • SGRQ-C组间平均差异-3·3(95%CI -6·4至-0·2,p=0·039)。
  • 血与痰嗜酸性粒细胞计数均显著下降,不良事件发生率与安慰剂相似。

核心结论

  • 在中至极重度COPD患者中,astegolimab未显著降低急性加重率,但与安慰剂相比改善了健康状态。

研究设计与样本

  • COPD-ST2OP为单中心、随机、双盲、安慰剂对照2a期试验,纳入中至极重度COPD患者,按1:1随机分组。
  • astegolimab组每4周皮下注射490 mg,安慰剂组皮下注射安慰剂,共44周。
  • 主要终点为48周急性加重率,采用负二项计数模型在意向治疗人群中评估,并按基线血嗜酸性粒细胞计数预设亚组分析。
  • 安全性在整个研究人群评估至第60周;试验注册号NCT03615040。

主要发现

  • 48周急性加重率astegolimab组为2·18(95%CI 1·59–2·78),安慰剂组为2·81(2·05–3·58),率比0·78(95%CI 0·53–1·14;p=0·19)。
  • 预设按血嗜酸性粒细胞分层:≤170个/μL者率比为0·69(0·39–1·21),>170个/μL者为0·83(0·49–1·40)。
  • SGRQ-C组间平均差异为-3·3(95%CI -6·4至-0·2;p=0·039),FEV1组间平均差异为40 mL(-10至90;p=0·094)。
  • 血嗜酸性粒细胞计数几何均值比组间差异为0·59(95%CI 0·51–0·69;p<0·001),痰嗜酸性粒细胞计数为0·25(0·19–0·33;p<0·001)。
  • 治疗中出现的不良事件发生率两组相似。

关键数值与推荐

  • 主要终点48周急性加重率率比0·78(95%CI 0·53–1·14;p=0·19),未达统计学显著。
  • SGRQ-C组间平均差异-3·3(95%CI -6·4至-0·2;p=0·039)。
  • FEV1组间平均差异40 mL(95%CI -10至90;p=0·094)。
  • 血嗜酸性粒细胞计数几何均值比0·59(95%CI 0·51–0·69;p<0·001),痰嗜酸性粒细胞计数0·25(95%CI 0·19–0·33;p<0·001)。

临床怎么用

  • 对中至极重度COPD,astegolimab未显示降低急性加重的获益,暂不支持以其为主要加重预防手段。
  • 健康状态评分改善及血、痰嗜酸性粒细胞下降提示ST2通路可能参与COPD炎症,但需进一步研究确定可获益人群。

局限性

  • 为单中心2a期试验,样本量有限,结果外推需谨慎。
  • 主要终点未达统计学显著,嗜酸性粒细胞亚组分析为预设但样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a heterogeneous inflammatory airway disease. The epithelial-derived IL-33 and its receptor ST2 have been implicated in airway inflammation and infection. We aimed to determine whether astegolimab, a selective ST2 IgG2 monoclonal antibody, reduces exacerbations in COPD. METHODS: COPD-ST2OP was a single-centre, randomised, double-blinded, placebo-controlled phase 2a trial in moderate-to-very severe COPD. Participants were randomly assigned (1:1) with a web-based system to received 490 mg subcutaneous astegolimab or subcutaneous placebo, every 4 weeks for 44 weeks. The primary endpoint was exacerbation rate assessed for 48 weeks assessed with a negative binomial count model in the intention-to-treat population, with prespecified subgroup analysis by baseline blood eosinophil count. The model was the number of exacerbations over the 48-week treatment period, with treatment group as a covariate. Safety was assessed in the whole study population until week 60. Secondary endpoints included Saint George's Respiratory Questionnaire for COPD (SGRQ-C), FEV1, and blood and sputum cell counts. The trial was registered with ClinicalTrials.gov, NCT03615040. FINDINGS: The exacerbation rate at 48 weeks in the intention-to-treat analysis was not significantly different between the astegolimab group (2·18 [95% CI 1·59 to 2·78]) and the placebo group (2·81 [2·05 to 3·58]; rate ratio 0·78 [95% CI 0·53 to 1·14]; p=0·19]). In the prespecified analysis stratifying patients by blood eosinophil count, patients with 170 or fewer cells per μL had 0·69 exacerbations (0·39 to 1·21), whereas those with more than 170 cells per μL had 0·83 exacerbations (0·49 to 1·40). For the secondary outcomes, the mean difference between the SGRQ-C in the astegolimab group versus placebo group was -3·3 (95% CI -6·4 to -0·2; p=0·039), and mean difference in FEV1 between the two groups was 40 mL (-10 to 90; p=0·094). The difference in geometric mean ratios between the two groups for blood eosinophil counts was 0·59 (95% CI 0·51 to 0·69; p<0·001) and 0·25 (0·19 to 0·33; p<0·001) for sputum eosinophil counts. Incidence of treatment-emergent adverse events was similar between groups. INTERPRETATION: In patients with moderate-to-very severe COPD, astegolimab did not significantly reduce exacerbation rate, but did improve health status compared with placebo. FUNDING: Funded by Genentech and National Institute for Health Research Biomedical Research Centres.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Yousuf AJ, Mohammed S, Carr L, et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022. PMID: 35339234. doi:10.1016/S2213-2600(21)00556-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。